PRE-APPROVAL PRODUCT AWARENESS:
COMPLIANT, CREATIVE ACTIVITIES and KOL INTERACTION
MARBLEHEAD, MA USA -- PHARMA UPDATE NEWS SERVICE(TM) -- AUGUST 30, 2006: So how do you create effective awareness of compounds or drugs when the legal boundaries aren't clear in the pre-market phase? With murky guidelines, managing KOLs and your pre-market educational activities is one of your biggest daily headaches and compliance worries. Trusted for delivering high-level advice, we've brought back Mark DuVal, former 3M Pharmaceuticals general counsel, to provide compliance commentary and help you push the envelope--within the rules--as you try to manage your pre-approval activities. In a back and forth style, Dr. Jeffrey Spears, PharmD, will present the scenarios and creative awareness strategies while Mark DuVal addresses the legal considerations.
LIVE Q & A:
- Scenario One:
Your company doesn't currently have a product in the marketplace and/or therapeutic segment so it needs to educate the end user and medical community. What pre-approval activities can be used? Any new ideas/concepts that will remain compliant.
- Scenario Two:
How can you make the medical community aware of product risks? Can and how should you develop a business plan for the KOLs in their specific geographies? Is an ROI analysis appropriate?
- Scenario Three:
Unapproved compound - can an MSL provide great questions/information on a first visit to create awareness without going outside of legal/regulatory boundaries?
- Scenario Four:
MSL's role in establishing/supporting CME and non-CME programs
- Scenario Five:
Vignette on establishing/supporting speaker programs and ad boards
Be sure to register to hear the full scenarios or to pre-submit an anonymous audience scenario, contact Bryan Cote at firstname.lastname@example.org or fax to 781/639-2982.
MEET OUR SPEAKERS:
Dr. Jeffrey Spears, PharmD is Senior Director of Medical Education at EMD Pharmaceuticals, a US affiliate of Merck KGaA, Darmstadt, Germany. He is responsible for EMD's field based medical program, CME and non-certified medical education grants, and health outcomes. Click here for full bio.
Mark DuVal, J.D., is President and Managing Partner of DuVal & Associates, where he counsels pharmaceutical, medical device, biotech, food and nutritional supplement companies. Click here for full bio.
FOR MORE INFORMATION:
For more information about PRE-APPROVAL PRODUCT AWARENESS: COMPLIANT, CREATIVE ACTIVITIES and KOL INTERACTION, call ePharmaceuticals at 877-437-4276, e-mail email@example.com, or visit: www.hcmarketplace.com/prod-4588-EN48858A.html
Join us TUESDAY, OCTOBER 10, 2006 for Pre-Approval Product Awareness: Compliant, Creative Activities and KOL Interaction beginning at 1 p.m. (Eastern). For more information visit our Website. If you prefer, call our Customer Service Team at (877) 437-4276. Just mention Source Code EN48858A to place your order. And remember, you may register now and pay later. Simply choose the "Bill Me" option and we will send you an invoice.
ePharmaceuticals, a division of Marblehead MA-based HCPro, Inc., provides business intelligence, compliance training, market research reports, and custom publishing services to the pharmaceutical industry. Publications include ePharm5, a daily business and marketing innovation newsletter, Medicare & Reimbursement Advisor Weekly, and Compliance Alert for Drug Sales and Marketing.